Grail jumps after Samsung backs rollout of cancer test in Asia

Grail

16/10/2025 13:55

** Shares of cancer diagnostic test maker Grail GRAL.O rise 16.3% to $87.80 premarket

** Samsung to invest $110 mln in GRAL to bring Galleri cancer detection test to South Korea – co

** Galleri is a blood test that screens for over 50 types of cancer by detecting abnormal DNA shed by tumors – GRAL

** Samsung C&T 028260.KS to lead rollout; expansion eyed for Japan and Singapore, co says

** Samsung Electronics 005930.KS to explore tech tie-ups with GRAL, including AI and health data integration

** Co says deal expected to close in early 2026, subject to conditions

** Up to last close, GRAL stock up ~323% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.pandey@thomsonreuters.com))